岩田 卓 (イワタ タカシ)

Iwata, Takashi

写真a

所属(所属キャンパス)

医学部 産婦人科学教室(婦人科) (信濃町)

職名

専任講師

学歴 【 表示 / 非表示

  • 1995年

    慶応義塾大学, 医学部, 医学科

    卒業

免許・資格 【 表示 / 非表示

  • 日本婦人科腫瘍学会婦人科腫瘍専門医

  • 日本臨床細胞学会細胞診専門医

  • 日本がん治療認定医機構がん治療認定医

  • 日本がん治療認定医機構暫定教育医

  • 日本産科婦人科学会専門医

 

研究分野 【 表示 / 非表示

  • ライフサイエンス / 産婦人科学

研究キーワード 【 表示 / 非表示

  • 婦人科腫瘍の免疫学的特性

  • 子宮頸癌の臨床病理的特徴

  • 子宮頸部での局所免疫応答

 

著書 【 表示 / 非表示

  • 子宮頚癌治療ガイドライン 2017年度版

    岩田 卓, 金原出版株式会社, 2017年07月

論文 【 表示 / 非表示

  • Evaluation of CD4<sup>+</sup> cells infiltration as a prognostic factor in cervical intraepithelial neoplasia 2

    Chen G., Iwata T., Sugawara M., Nishio H., Katoh Y., Kukimoto I., Aoki D.

    Journal of Gynecologic Oncology (Journal of Gynecologic Oncology)  34 ( 1 ) e2 2023年01月

    ISSN  20050380

     概要を見る

    Objective: To identify candidate predictors for the prognosis of cervical intraepithelial neoplasia 2 (CIN2) lesions and evaluate the prognostic value of the local immune response. Methods: One hundred fifteen CIN2 patients were enrolled. The percentage of p16-, minichromosome maintenance complex component 2-or apolipoprotein B mRNA editing enzyme catalytic subunit 3G (APOBEC3G)-positive cells was determined immunohistochemically. Tumor-infiltrating lymphocytes (TILs) in intertumoral lesions were scored using an automated system. CIN3 disease progression and regression rates were estimated by the Kaplan–Meier method. A case-control study was conducted to screen CIN2 prognostic factors in 10 regression and 10 progression patients. Selected factors were examined in a cohort study to determine their prognostic value for CIN2. Results: Among all participants, the cumulative progression and regression rates at 60 months were 0.477 and 0.510, respectively. In the case-control study, p16-and APOBEC3G-positive cells were higher in the progression group (p=0.043, p=0.023). Additionally, CD4+ cell infiltration was enhanced in the regression group (p=0.023). The cohort study revealed a significantly increased progression rate in patients with elevated p16-positive cells (p<0.001), and increased CD4+ TIL infiltration was associated with better regression (p=0.011). Kaplan– Meier analysis according to human papillomavirus (HPV) positivity revealed a greater CIN3 development risk in HPV16-positive patients than in HPV16-negative cases. Finally, multivariate analysis identified HPV16 infection and CD4+ TIL infiltration as independent prognostic factors in CIN2 regression. Conclusion: CD4+ TIL infiltration in intertumoral lesions was related with CIN2 regression. Our findings suggest CD4+ TIL infiltration may be useful for the triage of CIN2 patients.

  • Whole-genome analysis of human papillomavirus 67 isolated from Japanese women with cervical lesions

    Kogure G., Onuki M., Hirose Y., Yamaguchi-Naka M., Mori S., Iwata T., Kondo K., Sekizawa A., Matsumoto K., Kukimoto I.

    Virology Journal (Virology Journal)  19 ( 1 ) 157 2022年12月

     概要を見る

    Background: Human papillomavirus (HPV) type 67 is phylogenetically classified into Alphapapillomavirus species 9 (alpha-9) together with other carcinogenic types (HPV16, 31, 33, 35, 52 and 58), but is the only alpha-9 type defined as possibly carcinogenic. This study aimed to determine whole-genome sequences of HPV67 isolated from Japanese women with cervical cancer or cervical intraepithelial neoplasia (CIN) to better understand the genetic basis of the oncogenic potential of HPV67. Methods: Total cellular DNA isolated from cervical exfoliated cells that were single positive for HPV67 (invasive cervical cancer, n = 2; CIN3, n = 6; CIN 2, n = 1; CIN1, n = 2; the normal cervix, n = 1) was subjected to PCR to amplify HPV67 DNA, followed by next generation sequencing to determine the complete viral genome sequences. Variant lineages/sublineages were assigned through viral whole-genome phylogenetic analysis. The transcriptional activity of the virus early promoter was assessed by luciferase reporter assays in cervical cancer cell lines. Results: Phylogenetic analyses of HPV67 genomes from Japan (n = 12) revealed that 11 belonged to lineage A (sublineage A1, n = 9; sublineage A2, n = 2) and one belonged to lineage B. All cancer cases contained sublineage A1 variants, and one of these contained an in-frame deletion in the E2 gene. The long control region of the HPV67 genome did not induce transcription from the virus early promoter in HeLa cells, but showed weak transcriptional activity in CaSki cells. Conclusions: The single detection of HPV67 in cervical cancer and precancer specimens strongly suggests the carcinogenic potential of this rare genotype. The phylogenetic analysis indicates a predominance of lineage A variants among HPV67 infections in Japan. Since only 23 complete genome sequences of HPV67 had been obtained until now, the newly determined genome sequences in this study are expected to contribute to further functional and evolutionary studies on the genetic diversity of HPV67.

  • Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826

    Nishio S., Yonemori K., Usami T., Minobe S., Yunokawa M., Iwata T., Okamoto A., Aoki Y., Itamochi H., Takekuma M., Harano K., Yamamoto K., Maruko T., Ugai H., Tekin C., Colombo N., Fujiwara K., Hasegawa K., Ushijima K.

    Cancer Science (Cancer Science)  113 ( 11 ) 3877 - 3887 2022年11月

    ISSN  13479032

     概要を見る

    Pembrolizumab plus chemotherapy with or without bevacizumab demonstrated prolonged progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer in the phase 3, randomized, double-blind, placebo-controlled KEYNOTE-826 study. We report outcomes in patients enrolled in Japan. Patients received pembrolizumab 200 mg or placebo Q3W for up to 35 cycles plus chemotherapy (paclitaxel 175 mg/m2 + cisplatin 50 mg/m2 or carboplatin AUC 5) with or without bevacizumab 15 mg/kg. Dual primary endpoints were PFS per RECIST v1.1 by investigator assessment and OS in the global population; these were evaluated in patients with tumors with PD-L1 combined positive score (CPS) ≥1, all-comers, and PD-L1 CPS ≥10. Fifty-seven patients from Japan were randomized (pembrolizumab plus chemotherapy, n = 35; placebo plus chemotherapy, n = 22). Pembrolizumab plus chemotherapy improved PFS versus placebo plus chemotherapy in patients with PD-L1 CPS ≥1 (n = 51; hazard ratio [HR; 95% CI], 0.36 [0.16–0.77]), all-comers (n = 57; 0.45 [0.22–0.90]), and patients with PD-L1 CPS ≥10 (n = 25; 0.36 [0.12–1.07]). HRs (95% CI) for OS were 0.38 (0.14–1.01), 0.41 (0.17–1.00), and 0.37 (0.10–1.30), respectively. Incidence of grade 3–5 AEs was 94% in the pembrolizumab group and 100% in the placebo group. Consistent with findings in the global KEYNOTE-826 study, pembrolizumab plus chemotherapy with or without bevacizumab may prolong survival versus placebo plus chemotherapy with or without bevacizumab and had a manageable safety profile in Japanese patients with persistent, recurrent, or metastatic cervical cancer.

  • Regional differences in human papillomavirus type 52 prevalence among Japanese women with cervical intraepithelial neoplasia†

    Kukimoto I., Onuki M., Yamamoto K., Yahata H., Aoki Y., Yokota H., Konnai K., Nio A., Takehara K., Kamiura S., Tsuda N., Takei Y., Shimada M., Nakai H., Yoshida H., Motohara T., Yamazaki H., Nakamura K., Okunomiya A., Tasaka N., Ishikawa M., Hirashima Y., Shimoji Y., Mori M., Iwata T., Takahashi F., Yoshikawa H., Yaegashi N., Matsumoto K.

    Japanese journal of clinical oncology (Japanese journal of clinical oncology)  52 ( 10 ) 1242 - 1247 2022年10月

    ISSN  0368-2811

     概要を見る

    Although geographical differences in the distribution of human papillomavirus genotypes have been observed worldwide, no studies have reported on national differences in the prevalence of human papillomavirus types in Japan. Here, we report a cross-sectional study to explore regional differences in the prevalence of human papillomavirus types among Japanese women with cervical intraepithelial neoplasia or invasive cervical cancer. Using human papillomavirus genotyping data from the nationwide prospective study on human papillomavirus vaccine effectiveness, we compared the frequency of detection of 15 high-risk and two low-risk human papillomavirus types in each disease category between the women who visited hospitals located in eastern Japan and those who visited hospitals located in western Japan. The risk of cervical intraepithelial neoplasia progression was assessed by calculating a prevalence ratio of each human papillomavirus type for cervical intraepithelial neoplasia grade 2/3 versus grade 1. Among the human papillomavirus types studied, human papillomavirus 52 was detected significantly more frequently in western hospitals than in eastern hospitals in cervical intraepithelial neoplasia grade 1 patients, but was less frequent in cervical intraepithelial neoplasia grade 2/3. The prevalence of particular human papillomavirus types was not significantly different between patients in hospitals in eastern Japan and those in hospitals in western Japan for invasive cervical cancer. In both eastern and western hospitals, a higher risk of cervical intraepithelial neoplasia progression was observed in patients infected with human papillomavirus 16, 31 or 58. In contrast, there was a significantly higher prevalence of human papillomavirus 52 infection in women with cervical intraepithelial neoplasia grade 2/3 than in those with cervical intraepithelial neoplasia grade 1 in eastern hospitals (prevalence ratio, 1.93; 95% confidence interval, 1.48-2.58), but not in western hospitals (prevalence ratio, 1.03; 95% confidence interval, 0.83-1.30). Regional differences of human papillomavirus 52 prevalence in cervical intraepithelial neoplasia lesions may exist and emphasize the importance of continuous monitoring of human papillomavirus type prevalence throughout the country in order to accurately assess the efficacy of human papillomavirus vaccines.

  • 特集 AYA世代の女性ヘルスケア-対応と実際- Ⅳ.婦人科腫瘍・婦人科疾患への対策 1.子宮頸部病変の妊孕性温存手術

    田中 恒成, 岩田 卓

    産婦人科の実際 (金原出版)  71 ( 10 ) 1101 - 1105 2022年09月

    ISSN  05584728

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

全件表示 >>

総説・解説等 【 表示 / 非表示

  • 子宮頸癌に対する放射線治療後腟狭窄に対してヘガールを用いた腟拡張療法を施行しQOLの改善を得た4例の後方視的検討

    椎名 美季, 横田 めぐみ, 大野 あゆみ, 谷本 慧子, 千代田 達幸, 山上 亘, 弟子丸 亮太, 岩田 卓, 阪埜 浩司, 青木 大輔

    日本女性医学学会雑誌 ((一社)日本女性医学学会)  30 ( 1 ) 94 - 94 2022年10月

    ISSN  2185-8861

  • HPV検査を含んだ子宮頸がん検診アルゴリズムについて 細胞診陰性/HPV陽性の管理 Evidenceに基づく細胞診陰性HPV陽性症例の取り扱い

    西尾 浩, 岩田 卓, 青木 大輔

    日本臨床細胞学会雑誌 ((公社)日本臨床細胞学会)  61 ( Suppl.2 ) 400 - 400 2022年10月

    ISSN  0387-1193

  • 子宮頸部病変のフォローアップにおけるLC-1000ランク分類の臨床的有用性の検討

    仲村 勝, 西尾 浩, 岩田 卓, 青木 大輔

    日本臨床細胞学会雑誌 ((公社)日本臨床細胞学会)  61 ( Suppl.2 ) 560 - 560 2022年10月

    ISSN  0387-1193

  • 慢性骨盤痛患者に対する多診療科による対応について

    大野 あゆみ, 横田 めぐみ, 椎名 美季, 谷本 慧子, 吉浜 智子, 西尾 浩, 山上 亘, 弟子丸 亮太, 岩田 卓, 青木 大輔

    日本女性医学学会雑誌 ((一社)日本女性医学学会)  30 ( 1 ) 103 - 103 2022年10月

    ISSN  2185-8861

  • 骨粗鬆症患者における選択的エストロゲン受容体モジュレーター(SERM)の骨質,骨量改善効果についての検討

    谷本 慧子, 横田 めぐみ, 家谷 佳那, 椎名 美季, 大野 あゆみ, 吉浜 智子, 増田 健太, 千代田 達幸, 山上 亘, 弟子丸 亮太, 岩田 卓, 阪埜 浩司, 青木 大輔

    日本女性医学学会雑誌 ((一社)日本女性医学学会)  30 ( 1 ) 97 - 97 2022年10月

    ISSN  2185-8861

全件表示 >>

研究発表 【 表示 / 非表示

  • 子宮頸癌に対する放射線治療後膣狭窄に対してヘガールを用いた膣拡張療法を施行しQOLの改善を得た4例の後方視的検討

    椎名 美季, 横田 めぐみ, 大野 あゆみ, 谷本 慧子, 千代田 達幸, 山上 亘, 弟子丸 亮太, 岩田 卓, 阪埜 浩司, 青木 大輔

    第37回日本女性医学学会学術集会 (鳥取) , 

    2022年11月

  • 骨粗鬆症患者における選択的エストロゲン受容体モジュレーター(SERM)の骨質,骨量改善効果についての検討

    谷本 慧子, 横田 めぐみ, 家谷 佳那, 椎名 美季, 大野 あゆみ, 吉浜 智子, 増田 健太, 千代田 達幸, 山上 亘, 弟子丸 亮太, 岩田 卓, 阪埜 浩司, 青木 大輔

    第37回日本女性医学学会学術集会 (鳥取) , 

    2022年11月

  • 慢性骨盤痛患者に対する多診療科による対応について

    大野 あゆみ, 横田 めぐみ, 椎名 美季, 谷本 慧子, 吉浜 智子, 西尾 浩, 山上 亘, 弟子丸 亮太, 岩田 卓, 青木 大輔

    第37回日本女性医学学会学術集会 (鳥取) , 

    2022年11月

  • Evidenceに基づく細胞診陰性HPV陽性症例の取り扱い

    西尾 浩, 岩田 卓, 青木 大輔

    第61回日本臨床細胞学会秋期大会学術集会 (宮城県) , 

    2022年11月

  • 子宮頸部病変のフォローアップにおけるLC-1000ランク分類の臨床的有用性の検討

    仲村 勝, 西尾 浩, 岩田 卓, 青木 大輔

    第61回日本臨床細胞学会秋期大会学術集会 (宮城県) , 

    2022年11月

全件表示 >>

競争的研究費の研究課題 【 表示 / 非表示

  • 腫瘍浸潤リンパ球輸注療法(TIL療法)を実施した子宮頸癌患者の免疫応答解析

    2022年04月
    -
    2025年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 岩田 卓, 基盤研究(B), 補助金,  研究代表者

  • 子宮頸癌に対する腫瘍浸潤T細胞療法(TIL療法)実施にむけたTIL培養法の開発

    2019年04月
    -
    2022年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 岩田 卓, 基盤研究(B), 補助金,  研究代表者

  • HPV陰性子宮頸部腺癌の分子生物学的および腫瘍免疫学的特性の解明

    2015年04月
    -
    2018年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 岩田 卓, 基盤研究(C), 補助金,  研究代表者

 

担当授業科目 【 表示 / 非表示

  • メディカル・プロフェッショナリズムⅥ

    2022年度

  • 婦人科学講義

    2022年度

  • メディカル・プロフェッショナリズムⅥ

    2021年度

  • 婦人科学講義

    2021年度

  • 婦人科学講義

    2020年度

全件表示 >>

 

所属学協会 【 表示 / 非表示

  • 日本免疫学会

     
  • 婦人科悪性腫瘍研究機構

     
  • 日本癌免疫学会

     
  • 日本女性医学会

     
  • 日本産婦人科学会

     

全件表示 >>